Thus, the findings of an association between EGFR and tamoxifen-insensitivity in oesophageal adenocarcinoma cells may represent either a more aggressive tumour phenotype reflected in higher EGFR expression or the activation of an alternative pathway by which cell proliferation continues in the presence of the drug. The gene discussed is EGFR; the disease is esophageal adenocarcinoma.